Valuation : Impax Laboratories Inc

Market Cap 6.07B 5.23B 4.92B 4.49B 8.4B 574B 8.43B 58.11B 22.55B 294B 22.81B 22.31B 948B P/E 2026 *
38.8x
P/E 2027 * 19.7x
Enterprise Value 8.39B 7.22B 6.79B 6.21B 11.61B 792B 11.64B 80.29B 31.15B 407B 31.51B 30.83B 1,310B EV / Sales 2026 *
2.66x
EV / Sales 2027 * 2.35x
Free-Float
44.34%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 01/08/2019
Chief Executive Officer 54 01/08/2019
Director of Finance/CFO 58 07/11/2023
Director TitleAgeSince
Director/Board Member 59 07/11/2023
Director/Board Member 70 07/11/2023
Director/Board Member 52 07/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-2.92% - - 6.07B
-0.88%-2.15%+58.05%+105.91% 1,024B
-1.15%+2.68%+54.25%+71.29% 663B
-1.44%+0.38%+20.65%+75.54% 453B
+0.14%-0.47%+30.20%+40.61% 352B
-1.33%+4.72%+24.62%+47.60% 304B
-1.15%+0.30%-0.69%+11.83% 252B
-1.55%+1.11%+54.15%+72.13% 236B
-0.88%+1.15%-14.60%-54.84% 206B
-0.15%+3.65%+31.24%+100.90% 187B
Average -1.04%+1.09%+28.65%+52.33% 408.71B
Weighted average by Cap. -0.96%+0.55%+37.63%+67.00%

Financials

2026 *2027 *
Net sales 3.15B 2.71B 2.55B 2.33B 4.36B 298B 4.38B 30.17B 11.71B 153B 11.84B 11.59B 492B 3.43B 2.95B 2.78B 2.54B 4.75B 324B 4.76B 32.81B 12.73B 166B 12.88B 12.6B 535B
Net income 149M 128M 120M 110M 206M 14.05B 206M 1.42B 552M 7.21B 559M 547M 23.22B 295M 254M 239M 218M 408M 27.83B 409M 2.82B 1.09B 14.28B 1.11B 1.08B 46B
Net Debt 2.32B 1.99B 1.88B 1.71B 3.21B 219B 3.22B 22.17B 8.6B 112B 8.7B 8.51B 362B 2B 1.72B 1.62B 1.48B 2.76B 188B 2.77B 19.09B 7.41B 96.65B 7.49B 7.33B 311B
Logo Impax Laboratories Inc
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
-